Myricitrin

Myricitrin

SCHEMBL244345

C[C@H]1OC(Oc2c(-c3cc(O)c(O)c(O)c3)oc3cc(O)cc(O)c3c2=O)[C@@H](O)[C@@H](O)[C@@H]1O

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
P4HB P07237 5/20 1.00
KDM4E B2RXH2 5/20 1.00
MAPT P10636 4/20 1.00
POLB P06746 3/20 1.00
GAA P10253 3/20 1.00
L3MBTL1 Q9Y468 3/20 1.00
SLCO2B1 O94956 3/20 1.00
ALDH1A1 P00352 2/20 1.00
MPI P34949 1/20 1.00
NAMPT P43490 1/20 1.00
RECQL P46063 1/20 1.00
TDP1 Q9NUW8 1/20 1.00
EPHX2 P34913 4/20 0.82
XDH P47989 4/20 0.82
MAOA P21397 3/20 0.82
AKR1B1 P15121 2/20 0.82
PIM2 Q9P1W9 2/20 0.82
CA12 O43570 1/20 0.82
CA2 P00918 1/20 0.82
CA4 P22748 1/20 0.82

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Myricitrin SCHEMBL30427168 1.00 P4HB (1.00) P4HBKDM4EMAPTPOLBGAA
Myricitrin SCHEMBL30637444 1.00 P4HB (1.00) P4HBKDM4EMAPTPOLBGAA
Myricitrin SCHEMBL13240936 1.00 P4HB (1.00) P4HBKDM4EMAPTPOLBGAA
Myricitrin SCHEMBL6361658 1.00 P4HB (1.00) P4HBKDM4EMAPTPOLBGAA
Myricitrin SCHEMBL12640019 1.00 P4HB (1.00) P4HBKDM4EMAPTPOLBGAA
Myricitrin SCHEMBL226022 1.00 P4HB (1.00) P4HBKDM4EMAPTPOLBGAA
Myricitrin SCHEMBL226023 1.00 P4HB (1.00) P4HBKDM4EMAPTPOLBGAA
Myricitrin SCHEMBL22788153 1.00 P4HB (1.00) P4HBKDM4EMAPTPOLBGAA
Myricitrin SCHEMBL22822137 1.00 P4HB (1.00) P4HBKDM4EMAPTPOLBGAA
Myricitrin SCHEMBL29615613 1.00 P4HB (1.00) P4HBKDM4EMAPTPOLBGAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 162 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12454714-B2 Monbretin A (MbA) synthesis using a heterologous nucleic acid(s) encoding A MbA pathway enzyme THE UNIVERSITY OF BRITISH COLUMBIA (CA) 2025-10-28 US claimed
US-12163004-B2 Polymer composites WARNER BABCOCK INSTITUTE FOR GREEN CHEMISTRY, LLC (US) 2024-12-10 US claimed
CN-114460189-B Method for screening differential markers of ultra-high pressure treated blueberry juice and heat treated blueberry juice 沈阳农业大学 2024-04-12 CN claimed
WO-2023219526-A1 MULTITARGET ANTIVIRAL DIETARY SUPPLEMENT PROKIN MILAN (RS) 2023-11-16 WO claimed
US-11439655-B2 Compounds for use in wound healing and angiogenesis UNIVERSITY OF SOUTH CAROLINA (US) 2022-09-13 US claimed
CN-114460189-A Method for screening difference markers of blueberry juice subjected to ultrahigh pressure treatment and blueberry juice subjected to heat treatment 沈阳农业大学 2022-05-10 CN claimed
US-20210317497-A1 MONBRETIN A (MBA) SYNTHESIS USING A HETEROLOGOUS NUCLEIC ACID(S) ENCODING A MBA PATHWAY ENZYME THE UNIVERSITY OF BRITISH COLUMBIA (CA) 2021-10-14 US claimed
US-10028970-B2 Composition comprising cashew apple extract NATUREX (FR) 2018-07-24 US claimed
US-6872771-B1 Tire with rubber containing flavone THE GOODYEAR TIRE & RUBBER COMPANY (US) 2005-03-29 US claimed
JP-2003504327-A 2003-02-04 JP claimed
EP-1223928-A2 USE OF FLAVONES, COUMARINS AND RELATED COMPOUNDS TO TREAT INFECTIONS Prendergast, Patrick Thomas (IE) 2002-07-24 EP claimed
WO-2001003681-A2 USE OF FLAVONES, COUMARINS AND RELATED COMPOUNDS TO TREAT INFECTIONS PRENDERGAST PATRICK T (IE) 2001-01-18 WO claimed
JP-6293654-A None JP disclosed
US-12630450-B1 Somatic embryonic cell suspension for wastewater treatment King Faisal University (SA) 2026-05-19 US disclosed
US-20260124225-A1 THERAPEUTIC COMPOSITIONS AND METHODS FOR USING SAME KARNICK WILLIAM (US) 2026-05-07 US disclosed
CN-120937891-A Composition for reducing content of advanced glycosylation end product of food and application thereof 中国海洋大学 2025-11-14 CN disclosed
EP-1223928-A2 USE OF FLAVONES, COUMARINS AND RELATED COMPOUNDS TO TREAT INFECTIONS Prendergast, Patrick Thomas (IE) 2002-07-24 EP disclosed
CN-1298734-A Plant medicine for treating cardiovascular medicine and its preparing process WUHAN INST OF PHYTOLOGY CHINES (CN) 2001-06-13 CN disclosed
WO-2001003681-A2 USE OF FLAVONES, COUMARINS AND RELATED COMPOUNDS TO TREAT INFECTIONS PRENDERGAST PATRICK T (IE) 2001-01-18 WO disclosed
JP-H06293654-A ACTIVE OXYGEN SCAVENGING AGENT AND ALDOSE REDUCTASE INHIBITING AGENT NIPPON MEKTRON LTD 1994-10-21 JP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260124225-A1 THERAPEUTIC COMPOSITIONS AND METHODS FOR USING SAME GCG, MC4R, GLP1R P4HB 4451/4885KDM4E 1278/4885MAPT 1901/4885
US-11439655-B2 Compounds for use in wound healing and angiogenesis CUTA, VEGFA, MYB P4HB 2194/4885KDM4E 3724/4885MAPT 3977/4885
US-12630450-B1 Somatic embryonic cell suspension for wastewater treatment ALPG, PROX1, KIT P4HB 4827/4885KDM4E 542/4885MAPT 3642/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.